Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 25; no. 21; pp. 2993 - 2995
Main Authors van Heeckeren, Willem J, Ortiz, Jose, Cooney, Matthew M, Remick, Scot C
Format Journal Article
LanguageEnglish
Published United States 20.07.2007
Subjects
Angiogenesis Inhibitors - adverse effects
Angiogenesis Inhibitors - therapeutic use
Biomarkers - analysis
Clinical Trials, Phase I as Topic
Drug Approval
Drug Delivery Systems
Evaluation Studies as Topic
Female
Humans
Hypertension - chemically induced
Male
Maximum Tolerated Dose
Neoplasms - drug therapy
Neoplasms - mortality
Neovascularization, Pathologic - prevention & control
Prognosis
Proteinuria - chemically induced
Risk Assessment
Signal Transduction - drug effects
Survival Analysis
Treatment Outcome
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Vascular Endothelial Growth Factor A - physiology
Online AccessGet full text

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2007.11.5113